Abaloparatide TFA (BA 058 TFA) is a parathyroid hormone receptor 1 (PTHR1) analogue selected to be a potent and selective activator of the PTHR1 signaling pathway.
Abametapir (HA-44, BRN 0123183) is an inhibitor of metalloproteinases critical for louse survival and egg development.
Abametapir (HA-44, BRN 0123183) is an inhibitor of metalloproteinases critical for louse survival and egg development.
Abametapir (HA-44, BRN 0123183) is an inhibitor of metalloproteinases critical for louse survival and egg development.
Abarelix (R3827) is the first approved antagonist for the study of GnRH in advanced prostate cancer. Sequence:Ac-{d-2-Nal}-{d-4-Cpa}-{d-3-Pal}-S-{NMyr}-{d-Asp}-L-K(ipr)-P-{d-Ala}-NH2
Abarelix (R3827) is the first approved antagonist for the study of GnRH in advanced prostate cancer. Sequence:Ac-{d-2-Nal}-{d-4-Cpa}-{d-3-Pal}-S-{NMyr}-{d-Asp}-L-K(ipr)-P-{d-Ala}-NH2
Abarelix (R3827) is the first approved antagonist for the study of GnRH in advanced prostate cancer. Sequence:Ac-{d-2-Nal}-{d-4-Cpa}-{d-3-Pal}-S-{NMyr}-{d-Asp}-L-K(ipr)-P-{d-Ala}-NH2
Abarelix (R3827) is the first approved antagonist for the study of GnRH in advanced prostate cancer. Sequence:Ac-{d-2-Nal}-{d-4-Cpa}-{d-3-Pal}-S-{NMyr}-{d-Asp}-L-K(ipr)-P-{d-Ala}-NH2
Abatacept is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1. Abatacept binds to antigen presenting cells CD80 and CD86, blocks costimulatory signals and inhibits T cell activation, and is used in the study of rheumatoid arthritis and juvenile rheumatoid arthritis.
ABBV-744 is a first-in-class, orally active and selective inhibitor of the BDII domain of the BET family of proteins with IC50 values of 4-18 nM for BRD2, BRD3, BRD4, and BRDT for AML and metastatic desmoplasia-resistant prostate cancer.
ABBV-744 is a first-in-class, orally active and selective inhibitor of the BDII domain of the BET family of proteins with IC50 values of 4-18 nM for BRD2, BRD3, BRD4, and BRDT for AML and metastatic desmoplasia-resistant prostate cancer.
ABBV-744 is a first-in-class, orally active and selective inhibitor of the BDII domain of the BET family of proteins with IC50 values of 4-18 nM for BRD2, BRD3, BRD4, and BRDT for AML and metastatic desmoplasia-resistant prostate cancer.